What happened
DOAC plus potent P2Y12 increases bleeding without reducing ischemic events versus DOAC, clopidogrel, and aspirin.
“In the first trial of its kind, we have answered an important clinical question. These findings do not support the routine use of potent P2Y12 inhibitors in combination with direct oral anticoagulants in patients with AF and MI.”
Conference Coverage ↗
Potent P2Y12 inhibition should not routinely replace clopidogrel alongside a DOAC after PCI in AF with ACS.
X post ↗
Do not combine DOACs with potent P2Y12 inhibitors even for a set period, as bleeding risk is too high.
X post ↗
“EPIDAURUS was stopped for safety reasons: ticagrelor and prasugrel cause more bleeding than clopidogrel in atrial fibrillation patients undergoing PCI, and so far, there is nothing particularly surprising about that. But at this point, are we perhaps asking the wrong question?”
X ↗
Summarizes that DOAC plus 1-month intensified P2Y12 inhibition with prasugrel or ticagrelor raised bleeding without reducing ischemic events versus triple antithrombotic therapy, and the trial was stopped early for bleeding.
X post ↗Sophia Proneikos
“There is something extraordinary in the fact that one of the most perfect theatres of antiquity was built not in the centre of a great city, but in a sanctuary of healing. At the end of the 4th century BCE, among the hills of Argolis, in the Sanctuary of Asclepius at Epidaurus,”
X ↗Mohammed Al-Qadami
“EPIDAURUS: In AF patients with ACS-PCI, potent P2Y12 inhibition plus a DOAC increased bleeding without reducing ischaemic events. Routine use is not supported.”
X ↗Open questions from this trial that would benefit from expert input.
Answers are grounded in this paper and cite their sources.
Why the trial, tables, limitations, PICO, abstract, media & sources
Patients with atrial fibrillation undergoing PCI for acute coronary syndrome need anticoagulation plus antiplatelet therapy, a combination that trades ischaemic protection against serious bleeding. The optimal early regimen — including escalated single platelet inhibition for one month alongside a NOAC — remained undefined.
Does a 1-month regimen of DOAC plus a potent P2Y12 inhibitor (prasugrel or ticagrelor) reduce ischemic events compared to DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome?
| Outcome | Potent P2Y12 | Clopidogrel |
|---|---|---|
| Hierarchical composite: death, stent thrombosis, MI, ischemic stroke, systemic embolism, urgent revascularization Win-loss ratio 1.19 (95% CI 0.61-2.32; p=0.610) · no clear ischemic benefit; per-arm counts not reported |
Does a 1-month regimen of DOAC plus a potent P2Y12 inhibitor (prasugrel or ticagrelor) reduce ischemic events compared to DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome?
Experts read EPIDAURUS as a clear negative result: adding a potent antiplatelet drug to an oral anticoagulant after stenting in atrial fibrillation brought more bleeding and no fewer heart events, so it should not be used routinely.
The reaction is one-sided. Clinicians who commented, including the trial's investigator, agree the results argue against swapping in the stronger antiplatelet drugs alongside an anticoagulant, even for a short time. The live question, raised by Davide Capodanno, is whether the field is asking the wrong question and should instead test briefly stopping the anticoagulant.
Several clinicians state the same practice message in their own posts: potent P2Y12 inhibitors should not be routinely combined with a DOAC in AF patients with ACS or MI, because bleeding rose without any ischemic benefit.
2 takes classified by contention axis so far — the map appears as more land.
Capodanno asks whether the field is asking the wrong question. As Heine relays from Capodanno's discussion, the next strategy to be tested is temporarily stopping the DOAC in AF-ACS rather than escalating antiplatelet therapy.
Where verified peers stand
Peer votes count verified clinicians only (n=0).
In patients with atrial fibrillation and acute coronary syndrome, a 1-month strategy of DOAC plus a potent P2Y12 inhibitor (prasugrel or ticagrelor) increases bleeding without reducing ischemic events compared to clopidogrel.
The selection of the optimal antithrombotic regimen in patients with atrial fibrillation and acute coronary syndrome remains challenging. Previous trials have demonstrated that dual antithrombotic therapy (DAT), consisting of direct oral anticoagulants (DOACs) plus a P2Y12 inhibitor, reduces bleeding compared to a triple-therapy regimen using vitamin K antagonists. However, subsequent meta-analyses have suggested an increased risk of ischemic events with DAT, particularly within the first month of treatment. Clopidogrel has been the predominant P2Y12 inhibitor used across these studies, despite the risk of high on-treatment platelet reactivity when using this drug. In this study, we conducted an open-label, randomized controlled trial (EPIDAURUS) in patients with atrial fibrillation and acute coronary syndrome, designed to assess the efficacy and safety of a 1-month regimen of DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) compared to DOAC plus clopidogrel and in-hospital aspirin. The primary outcomes of the trial were an efficacy endpoint, recurrent ischemic events and safety endpoints, including death and major bleeding, which were evaluated 6 weeks after randomization using separate win−loss ratio analyses. The study was prematurely terminated after enrollment of 602 patients (154 female) of an expected 1,474 patients, owing to safety concerns raised by the Data and Safety Monitoring Board. Exploratory analyses of secondary safety endpoints, including bleeding type ≥2 and ≥3 according to the Bleeding Academic Research Consortium scale, revealed that, compared to clopidogrel and in-hospital aspirin, treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications. These findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population. ClinicalTrials.gov identifier: NCT04981041 .
Rizas et al. (2026) conducted an RCT in Atrial fibrillation and acute coronary syndrome (n=602). DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) vs. DOAC plus clopidogrel and in-hospital aspirin was evaluated on Hierarchic composite of death, stent thrombosis, myocardial infarction, ischemic stroke, systemic thromboembolism and urgent revascularization (WLR 1.19, 95% CI 0.61-2.32, p=0.610). In patients with atrial fibrillation and acute coronary syndrome, a 1-month regimen of a DOAC plus a potent P2Y12 inhibitor did not reduce ischemic events but increased bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: